JP2009544318A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544318A5
JP2009544318A5 JP2009521850A JP2009521850A JP2009544318A5 JP 2009544318 A5 JP2009544318 A5 JP 2009544318A5 JP 2009521850 A JP2009521850 A JP 2009521850A JP 2009521850 A JP2009521850 A JP 2009521850A JP 2009544318 A5 JP2009544318 A5 JP 2009544318A5
Authority
JP
Japan
Prior art keywords
influenza virus
polypeptide
particle
virus
chimeric influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009521850A
Other languages
English (en)
Japanese (ja)
Other versions
JP5683811B2 (ja
JP2009544318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/016900 external-priority patent/WO2008094197A2/en
Publication of JP2009544318A publication Critical patent/JP2009544318A/ja
Publication of JP2009544318A5 publication Critical patent/JP2009544318A5/ja
Application granted granted Critical
Publication of JP5683811B2 publication Critical patent/JP5683811B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009521850A 2006-07-27 2007-07-27 キメラインフルエンザウイルス様粒子 Expired - Fee Related JP5683811B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83420006P 2006-07-27 2006-07-27
US60/834,200 2006-07-27
US87892007P 2007-01-05 2007-01-05
US60/878,920 2007-01-05
PCT/US2007/016900 WO2008094197A2 (en) 2006-07-27 2007-07-27 Chimeric influenza virus-like particles

Publications (3)

Publication Number Publication Date
JP2009544318A JP2009544318A (ja) 2009-12-17
JP2009544318A5 true JP2009544318A5 (https=) 2010-08-19
JP5683811B2 JP5683811B2 (ja) 2015-03-11

Family

ID=39674641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521850A Expired - Fee Related JP5683811B2 (ja) 2006-07-27 2007-07-27 キメラインフルエンザウイルス様粒子

Country Status (6)

Country Link
US (1) US9439959B2 (https=)
EP (1) EP2044198A4 (https=)
JP (1) JP5683811B2 (https=)
AU (1) AU2007345768B2 (https=)
CA (1) CA2659275C (https=)
WO (1) WO2008094197A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
DK2134360T3 (en) 2007-03-14 2016-02-22 Takeda Vaccines Inc Purification of virus-like particle
AU2009319979B2 (en) * 2008-11-03 2016-10-20 Takeda Vaccines, Inc. Improved methods for isolating enveloped virus-based VLPs free of infectious agents
WO2010058236A1 (es) * 2008-11-19 2010-05-27 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante de vector viral inactivado
US20120121710A1 (en) * 2009-03-27 2012-05-17 Arizona Board Of Regents For And On Behalf Of Arizona State University Mucosal Immunization
ES2588183T3 (es) * 2009-03-31 2016-10-31 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal
AU2010243489A1 (en) * 2009-05-01 2011-12-22 Redbiotec Ag Recombinant virus-like particles encoded by multi-gene vector
US9278998B2 (en) 2009-07-02 2016-03-08 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
WO2011056899A2 (en) * 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
BR112013011069A2 (pt) 2009-11-05 2017-03-28 Padgett Hal geração de partículas antigênicas semelhantes a virus através de ligações de proteína-proteína
EP2519539A4 (en) * 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
US8956618B2 (en) * 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
CN103002909B (zh) * 2010-03-29 2016-06-29 国家科学研究中心 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途
WO2012040406A2 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
BR112013007946B1 (pt) 2010-10-04 2022-07-12 Massachusetts Institute Of Technology Composições farmacêuticas e imunogênicas compreendendo polipeptídeos de hemaglutinina
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
KR101745472B1 (ko) * 2015-04-15 2017-06-12 대한민국 조류인플루엔자 바이러스의 세포 감염을 저해하는 물질을 선별하는 방법
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
JP7110119B2 (ja) 2016-06-03 2022-08-01 サノフィ パスツール インコーポレイティッド 改変インフルエンザヘマグルチニンポリペプチドの修飾
WO2021085650A1 (ja) * 2019-10-31 2021-05-06 有限会社根路銘生物資源研究所 ワクチン
CN113827715B (zh) * 2020-06-23 2024-07-05 普莱柯生物工程股份有限公司 一种抗h7亚型和h5亚型禽流感病毒的疫苗组合物、及其制备方法和应用
CN113264989A (zh) * 2021-05-17 2021-08-17 吉林大学 一种h9n2亚型禽流感嵌合病毒样颗粒制备方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485729B1 (en) * 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
JP4484969B2 (ja) * 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
MXPA02012818A (es) 2000-06-23 2003-05-14 Gov Health & Human Serv Vacunas de virus sincitales respiratoriso que expresan antigenos protectores a partir de genes proximos promotores.
JP5008244B2 (ja) * 2000-06-23 2012-08-22 ワイス・ホールディングズ・コーポレイション 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー
DE60127675T2 (de) 2000-06-28 2007-12-27 Fuji Nihon Seito Corp. Neuartige insulin synthase und verfahren zur herstellung von insulin durch anwendung derselben
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US20030049607A1 (en) 2001-03-12 2003-03-13 Tsvika Greener Compositions and methods for the modulation of viral maturation
EP2292772A1 (en) 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
GB0202569D0 (en) * 2002-02-04 2002-03-20 Oxford Biomedica Ltd Delivery means
CA2483640A1 (en) * 2002-05-16 2003-11-27 Bavarian Nordic A/S Fusion protein of hiv regulatory/accessory proteins
DE60335139D1 (de) * 2002-05-17 2011-01-05 Univ Emory Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen
WO2004042001A2 (en) 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
CA2488856A1 (en) 2002-06-20 2003-12-31 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
GB0226722D0 (en) 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US6910730B2 (en) * 2002-12-25 2005-06-28 Shiroki Corporation Mounting device for mounting a cable-operated window regulator
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8080255B2 (en) * 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
WO2006039701A1 (en) 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
JP5714799B2 (ja) * 2005-10-18 2015-05-07 ノババックス インコーポレイテッド 機能的インフルエンザウイルス様粒子（ｖｌｐ）
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
AU2009279456B2 (en) * 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity

Similar Documents

Publication Publication Date Title
JP2009544318A5 (https=)
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
Panahi et al. An overview on the treatments and prevention against COVID-19
Tornesello et al. Virus-like particles as preventive and therapeutic cancer vaccines
US20260077031A1 (en) Nucleic acids encoding human endogenous retrovirus k (herv-k) envelope proteins containing modified immunosuppressive domains (isd) and uses thereof
RU2609645C2 (ru) Экспрессионные системы
Lundstrom Replicon RNA viral vectors as vaccines
Lundstrom Alphavirus-based vaccines
JP2010535026A5 (https=)
JP2016534034A5 (https=)
Wang et al. Protective efficacy of the conserved NP, PB1, and M1 proteins as immunogens in DNA-and vaccinia virus-based universal influenza A virus vaccines in mice
JP2015505299A5 (https=)
JP2016513115A5 (https=)
JP2016516723A5 (https=)
JP2017035093A5 (https=)
JP2013216685A5 (https=)
JP2015506705A5 (https=)
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
PH12019500591A1 (en) Canine adenovirus vectors
JP2013510091A5 (https=)
Singh et al. An alphavirus-based therapeutic cancer vaccine: from design to clinical trial
RU2015135890A (ru) Композиция вакцины
IL305911A (en) Multifunctional nanoparticle vaccines for influenza
CA3023791A1 (en) Combination prime: boost therapy
Hong et al. Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development